Enbrel

Type: Product
Name: Enbrel
First reported 2 hours ago - Updated 1 hour ago - 1 reports

Green nail syndrome needs persistent treatment

Dear Dr. Roach • For the past four months, I have had an infection around the cuticle of my right index finger. There is green coloration under the nail near the cuticle, and the nail grew rather deformed. I am a gardener and a homemaker, so I tend to ... [Published STLtoday.com - 2 hours ago]
First reported 14 hours ago - Updated 14 hours ago - 1 reports

Stroke treatment has 'dramatic effect'

The former Invercargill police officer having experimentalstroke recovery treatment in the United States is making''remarkable progress'', a friend says.Brian Cowie had a stroke almost three years ago, when he was47, that left him with pain, fatigue and ... [Published Otago Daily Times - 14 hours ago]
First reported Sep 17 2014 - Updated Sep 17 2014 - 1 reports

Survey: RA Drug Market Driven by Uptake of Oral Jak Inhibitors and Non–TNF-Alpha Biologics

Biosimilars expected to challenge branded biologicsDecision Resources Group, a health care research firm located in Burlington, Mass., finds that the rheumatoid arthritis (RA) disease-modifying antirheumatic drug market will increase from $14 billion ... [Published PT Community - Sep 17 2014]
Entities: Biologics, Biology, Drugs
First reported Sep 17 2014 - Updated Sep 17 2014 - 1 reports

Amgen, Inc. Poised To Break Higher

After hitting more highs over the past month, the last week or two has been somewhat of a choppy period of time in the stock market.The end of last week and start to this week drew a lot of stocks lower, and as has commonly been the case this year, biotech ... [Published Benzinga.com - Sep 17 2014]
First reported Sep 17 2014 - Updated Sep 17 2014 - 1 reports

Sick Days Decreased in Psoriasis Patients on Etanercept

Gladman DD: Psoriatic arthritis. Dermatol Ther 2004, 17:350–363.Gottlieb AB, Chao C, Dann F: Psoriasis comorbidities. J Dermatol Treat 2008, 19:5–21.Mease P: Management of psoriatic arthritis: the therapeutic interface between rheumatology and dermatology. ... [Published General Medicine eJournal - Sep 17 2014]
First reported Sep 17 2014 - Updated Sep 17 2014 - 2 reports

Hisun’s Biosimilar Enbrel To Get CFDA Site Inspection

Article # 28140916014Posted: Sep. 17, 2014 1:55 AM GMTExecutive SummaryThe China FDA’s website indicates that Hisun Pharma ’s “ AnBaiNuo ”, a biosimilar version of Amgen and Pfizer ’s Enbrel (etanercept), will be on-site inspected within this month for ... [Published Health News Daily - Sep 17 2014]
First reported Sep 16 2014 - Updated Sep 16 2014 - 1 reports

No joints about it

Arthritis, by definition, is inflammation of the joints. Many, many people suffer from aches and pains from old injuries, physical traumas, and regular wear and tear from every-day living. Osteoarthritis is caused by degradation of the bone and cartilage ... [Published Penticton Herald - Sep 16 2014]
First reported Sep 12 2014 - Updated Sep 12 2014 - 1 reports

Etanercept Plus Methotrexate More Effective on Psoriasis

Reuters Health InformationBy Rob GoodierSeptember 11, 2014NEW YORK (Reuters Health) - According to a new review, there's generally only weak evidence for combining systemic therapies for psoriasis, except for one pairing: etanercept plus methotrexate ... [Published American Journal of Public Health - Sep 12 2014]
First reported Sep 10 2014 - Updated Sep 10 2014 - 1 reports

Pfizer (PFE) Presents at Morgan Stanley Healthcare Conference (Transcript)

David Risinger - Morgan StanleyOkay, so thanks everybody for joining our next session. It’s my pleasure to welcome Pfizer. I first need to refer you to disclaimers at www.morganstanley.com/researchdisclosures and I'm happy to welcome Geno Germano and ... [Published Seeking Alpha - Sep 10 2014]
First reported Sep 03 2014 - Updated Sep 03 2014 - 2 reports

TNF-alpha Inhibition May Improve Psoriasis, CVD Risk

Dr. Graeme M. Lipper reviews a study showing that etanercept produced a reduction in 6 proinflammatory markers.Medscape Dermatology ... [Published Medscape - Sep 03 2014]
Entities: Psoriasis, Risk, Enbrel
First reported Aug 28 2014 - Updated Aug 29 2014 - 2 reports

Protalix Announces Conference Call to Discuss ELELYSO Pediatric Approval and Provide Updates on Additional Programs

CARMIEL, Israel, Aug. 28, 2014 (GLOBE NEWSWIRE) -- . (NYSE MKT:PLX) (TASE:PLX), announced today that it will host a conference call on Wednesday, September 3, 2014 at 8:30am ET to discuss the recent approval of ELELYSO for pediatric patients as jointly ... [Published EMoneyDaily - Aug 28 2014]
First reported Aug 26 2014 - Updated Aug 26 2014 - 1 reports

Ixekizumab superior to etanercept in psoriasis trials

Ixekizumab (Eli Lilly) has demonstrated superiority to etanercept (Enbrel, Amgen) in phase 3 studies for the treatment of moderate-to-severe plaque psoriasis.In three studies, patients were assigned to receive ixekizumab (80 mg every two or four weeks, ... [Published Dermatology Times - Aug 26 2014]

Quotes

"It's remarkable progress and very exciting for Brian and"
Dr Yoo added: "Xeljanz will compete for patient share in two areas of the RA treatment algorithm. First, with the non-TNF-alpha inhibitor biologics for patients who fail to respond to TNF-alpha inhibitors. Second, to a lesser degree, it has the potential to compete at the same line of therapy as the TNF-alpha inhibitors, in patients with an inadequate response to methotrexate."
"Ranbaxy has, under their license, quite aa few markets in southeast Asia and North Africa," he said. "We're also working with other partners in places like Latin America."
As Mr Bhan noted, the global biotechnology sector has been undergoing dynamic changes in terms of perspective and priorities. "While we may capitalize on our strengths in bio generics, innovation is needed for the development of new products and processes. There is a need to create a critical mass of small business units that have the potential to drive innovation" he added

More Content

All (192) | News (152) | Reports (0) | Blogs (37) | Audio/Video (0) | Fact Sheets (3) | Press Releases (0)
sort by: Date | Relevance
Green nail syndrome needs persistent treatment [Published STLtoday.com - 2 hours ago]
Markers for determination of patient responsive... [Published PharmCast - 14 hours ago]
Stroke treatment has 'dramatic effect' [Published Otago Daily Times - 14 hours ago]
“The painkillers market will reach $68.2 billio... [Published Prlog - Sep 19 2014]
Orexigen Therapeutics (OREX) Presents at Bank o... [Published Seeking Alpha - Sep 18 2014]
Study: Little difference in shingles risk among... [Published Dermatology Times - Sep 18 2014]
Survey: RA Drug Market Driven by Uptake of Oral... [Published PT Community - Sep 17 2014]
Amgen, Inc. Poised To Break Higher [Published Benzinga.com - Sep 17 2014]
Rheumatoid arthritis drug market will grow to $... [Published Pharma Letter - Sep 17 2014]
Sick Days Decreased in Psoriasis Patients on Et... [Published General Medicine eJournal - Sep 17 2014]
Hisun’s Biosimilar Enbrel To Get CFDA Site Insp... [Published Health News Daily - Sep 17 2014]
Hisun’s Biosimilar Enbrel To Get CFDA Site Insp... [Published BioPortfolio - Sep 17 2014]
No joints about it [Published Penticton Herald - Sep 16 2014]
Epirus, Ranbaxy win India approval for arthriti... [Published Yahoo! Finance UK and Ireland - Sep 15 2014]
Epirus, Ranbaxy win India approval for arthriti... [Published CNBC - Sep 15 2014]
India’s Dept of Biotech plans financial help fo... [Published Pharma Letter - Sep 15 2014]
Report: Psoriatic arthritis market will reach m... [Published Center Watch - Sep 12 2014]
Etanercept Plus Methotrexate More Effective on ... [Published American Journal of Public Health - Sep 12 2014]
Management of cataracts in the setting of perip... [Published Eye World - Sep 11 2014]
Baxalta: Baxter's newly named biopharma spinout... [Published FierceBiotech - Sep 11 2014]
Patent Application Titled "Chlorobis Copper (I)... [Published Pharmacy Choice - Sep 11 2014]
First Biosimilar Drugs Challenge Unfolds in Fed... [Published National Law Journal - Sep 11 2014]
Pfizer (PFE) Presents at Morgan Stanley Healthc... [Published Seeking Alpha - Sep 10 2014]
Premium-price biologicals and novel therapies w... [Published Pharma Letter - Sep 10 2014]
Psoriatic arthritis market to soar 66%, boosted... [Published Pharma Times - Sep 10 2014]
Explaining immunogenicity [Published Irish Medical Times - Sep 10 2014]
Central but not systemic administration of XPro... [Published 7thSpace - Sep 10 2014]
Tailored Approach to Lower Anti-TNF Dose in Ank... [Published General Medicine eJournal - Sep 10 2014]
Challenging Consensus On PCSK9 Inhibitors: Focu... [Published Seeking Alpha - Sep 08 2014]
Xencor announces management changes [Published Individual.com - Sep 08 2014]
1 2 3 4 5 6 7
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Lilly's Ixekizumab proves superior in Phase 3 P... [Published PBR - News - Aug 22 2014]
Eli Lilly and Company's investigational medicine ixekizumab was statistically superior to etanercept and placebo on all skin clearance measures in Phase 3 studies, the company said in disclosing top-line results from its pivotal UNCOVER studies in moderate-to-severe ...
Lilly's Ixekizumab Superior to Etanercept and P... [Published PR Newswire: Health - Aug 21 2014]
INDIANAPOLIS, Aug. 21, 2014 /PRNewswire/ -- Ixekizumab met all primary and key secondary objectives across three pivotal studies of 3,866 patients, the largest Phase 3 moderate-to-severe plaque psoriasis program to dateIxekizumab was superior to etanercept ...
Biological Drugs Market Will Reach USD 2, 87,13... [Published PR.com Press Releases - Aug 19 2014]
New York, NY, August 19, 2014 --( PR.com )-- Persistence Market Research (http://www.persistencemarketresearch.com) Released New Market Report on "Global Market Study on Biological Drugs: North America to Witness Highest Growth by 2020” the global biological ...
Doctor Criticized For His Questionable 'Treatme... [Published Techdirt - Jul 26 2014]
Dr. Edward Tobinick was the subject of an LA Times article in 2013 -- I'd link to it, but it appears to have disappeared, though I don't know why -- which highlighted his (apparently now discontinued) practice of prescribing a particular drug, Enbrel, ...
Legal thuggery directed at Steve Novella and Sc... [Published ScienceBlogs : Combined Feed - Jul 23 2014]
If there’s one characteristic of supporters of dubious medicine, it’s that they hate criticism. Whereas your average skeptic might not like criticism—sensitivity to criticism being a human trait and all—science- and evidence-based criticism tends to ...
1 2 3 4 5 6 7 8
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.